https://orcid.org/0000-0003-1803-2046
References
- Patruno C, Ayala F, Megna M, et al. Patient-physician relationship in patients with psoriasis. Indian J Dermatol Venereol Leprol. 2012;78(2):228.
- De Simone C, Caldarola G, Moretta G, et al. Moderate-to-severe psoriasis and pregnancy: impact on fertility, pregnancy outcome and treatment perspectives. G Ital Dermatol Venereol. 2019;154(3):305–314.
- Warren RB, Reich K, Langley RG, et al. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. Br J Dermatol. 2018;179(5):1205–1207.
- Porter ML, Lockwood SJ, Kimball AB. Update on biologic safety for patients with psoriasis during pregnancy. Int J Womens Dermatol. 2017;3(1):21–25.
- Raychaudhuri SP, Navare T, Gross J, et al. Clinical course of psoriasis during pregnancy. Int J Dermatol. 2003;42(7):518–520.
- Clowse MEB, Scheuerle AE, Chambers C, et al. Pregnancy outcomes after exposure to certolizumab pegol: updated results from a pharmacovigilance safety database. Arthritis Rheumatol. 2018;70(9):1399–1407.
- Meroni M, Generali E, Guidelli GM, et al. THU0319 Overall safety of 7-week secukinumab exposure during pregnancy in women with psoriatic arthritis. Ann Rheumat Dis. 2018;77(Suppl 2):377–378.
- Nardin C, Colas M, Curie V, et al. Pregnancy after tubal sterilization in a woman treated with biologics for severe psoriasis. Dermatol Ther (Heidelb). 2018;8(2):323–326.